Parasites & Vectors (Mar 2014)

Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration

  • Feli M Walther,
  • Allan J Paul,
  • Mark J Allan,
  • Rainer KA Roepke,
  • Martin C Nuernberger

DOI
https://doi.org/10.1186/1756-3305-7-86
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 3

Abstract

Read online

Abstract Background Fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tick-control after a single oral dose. This study investigated the safety of oral administration of fluralaner at 3 times the highest expected clinical dose to Multi Drug Resistance Protein 1 (MDR1(-/-)) gene defect Collies. Methods Sixteen Collies homozygous for the MDR1 deletion mutation were included in the study. Eight Collies received fluralaner chewable tablets once at a dose of 168 mg/kg; eight sham dosed Collies served as controls. All Collies were clinically observed until 28 days following treatment. Results No adverse events were observed subsequent to fluralaner treatment of MDR1(-/-) Collies at three times the highest expected clinical dose. Conclusions Fluralaner chewable tablets are well tolerated in MDR1(-/-) Collies following oral administration.

Keywords